Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02491099 · ClinicalTrials.gov registry record · Phase 2
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
A Phase 2 study of HER2/Neu+ Uterine Serous Carcinoma, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT02491099: Recruiting Phase 2 study of HER2/Neu+ Uterine Serous Carcinoma, sponsored by Yale University.
NCT02491099 is a Phase 2 study of HER2/Neu+ Uterine Serous Carcinoma that is actively recruiting participants, run by Yale University. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02491099, a Phase 2 study of HER2/Neu+ Uterine Serous Carcinoma, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
Primary Objective: To assess the activity of Afatinib in patients with persistent or recurrent uterine serous carcinoma overexpressing HER2/neu with the frequency of patients who survive progression-free for at least 6 months after initiating therapy. Secondary Objectives: To assess objective response rate and durable disease control rate. To assess overall survival. To assess the safety profile of Afatinib in uterine serous carcinoma patients.
Primary Outcome
Progression free survival for at least 6 months after initiating therapy
Conditions Studied
Interventions
- DRUG Afatinib
Study Locations (3)
Arizona
- University of Arizona Cancer Center - Tucson
Connecticut
- Yale New Haven Hospital - New Haven
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-06 |
| Est. Completion | 2028-07 |
| Phase | Phase 2 |
What NCT02491099 shows while recruiting
NCT02491099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with HER2/Neu+ Uterine Serous Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Afatinib is the first listed.
NCT02491099 reports a single indexed study location in Arizona, Connecticut, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02491099 about?
NCT02491099 is a clinical study titled "A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma". Primary Objective: To assess the activity of Afatinib in patients with persistent or recurrent uterine serous carcinoma overexpressing HER2/neu with the frequency of patients who survive progression-free for at least 6 months after initiating therapy. Secondary Objectives: To assess objective respon...
What is the current status of trial NCT02491099?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2015-06. Estimated completion is 2028-07.
What conditions does trial NCT02491099 study?
This clinical trial studies the following conditions: HER2/Neu+ Uterine Serous Carcinoma.
What interventions are being tested in trial NCT02491099?
The interventions under investigation include: Afatinib (DRUG).
Who is sponsoring clinical trial NCT02491099?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02491099 being conducted?
This trial has 3 study locations across Arizona, Connecticut, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02491099's enrollment target sits among peer trials
50 1195th of 2000 higher than 741 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia